— Know what they know.
Not Investment Advice
Also trades as: 0I5P.L (LSE) · $vol 0M

CBAY NASDAQ

CymaBay Therapeutics, Inc.
1W: +0.1% 1M: +0.8% 3M: +46.2% 1Y: +262.9% 3Y: +579.5% 5Y: +172.2%
$32.48
Last traded 2024-03-25 — delisted
NASDAQ · Healthcare · Biotechnology · $3.7B mcap · 97M float · 4.31% daily turnover

Balance Sheet Trends

Total Assets
$435M +206.4% ▲
5Y CAGR: +18.4%
Total Liabilities
$142M +34.8% ▲
5Y CAGR: +54.2%
Shareholders Equity
$292M +708.4% ▲
5Y CAGR: +11.4%
Cash & Investments
$394M +191.0% ▲
5Y CAGR: +17.2%
Total Debt
$114M +25.9% ▲
Net Debt
-$92M -230.3% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2019FY2020FY2021FY2022FY2023
— Assets —
Cash$25M$28M$126M$20M$207M
Short-Term Investments$166M$118M$61M$115M$188M
Cash & ST Investments$191M$146M$187M$135M$394M
Net Receivables$687K$277K$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$11M$5M$5M$3M$10M
Total Current Assets$203M$152M$191M$138M$404M
Property, Plant & Equip.$3M$2M$1M$870K$6M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$8M$0$22M
Other Non-Current Assets$160K$207K$2M$3M$3M
Total Non-Current Assets$3M$2M$11M$4M$31M
Total Assets$206M$154M$202M$142M$435M
— Liabilities —
Accounts Payable$3M$231K$3M$1M$4M
Short-Term Debt$407K$482K$567K$664K$10M
Deferred Revenue$0$0$0$0$2M
Other Current Liabilities$15M$9M$15M$14M$21M
Total Current Liabilities$18M$10M$18M$15M$37M
Long-Term Debt$2M$1M$51M$90M$104M
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$2M$1M$51M$90M$106M
Total Liabilities$19M$11M$69M$106M$142M
— Equity —
Common Stock$7K$7K$8K$8K$11K
Retained Earnings-$626M-$677M-$767M-$873M-$978M
Accumulated OCI$80K$8K-$13K-$326K$144K
Total Stockholders Equity$186M$143M$133M$36M$292M
Total Liabilities & Equity$206M$154M$202M$142M$435M
— Key Metrics —
Total Debt$2M$2M$52M$91M$114M
Net Debt-$23M-$26M-$74M$71M-$92M
Total Investments$166M$118M$69M$115M$210M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms